A multidisciplinary team from Northwestern Medicine — Ocular Oncologist Chris Bowen, MD, Neurooncologist Karan Dixit, MD, and Neurosurgeon Stephen Magill, MD, PhD — join this episode of the Better Edge podcast. They discuss primary vitreoretinal lymphoma, a rare and complex disease that poses unique challenges in both diagnosis and treatment, and unravel the mysteries surrounding this condition and its management.Physicians who listen to this podcast may claim continuing medical education credit after listening to an episode of this program. Target AudiencePhysicians and other healthcare providers / multiple specialties Learning ObjectivesAt the conclusion of this activity, participants will be able to:Discuss the latest clinical advances and complex cases in the various Northwestern Memorial Hospital departments.Identify the latest research interest and initiatives of NMH physicians.Disseminate evidence-based patient care into practice. Accreditation StatementThe Northwestern University Feinberg School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Credit Designation StatementThe Northwestern University Feinberg School of Medicine designates this Enduring Material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Disclosure information: Speaker(s):Dr. Karan Dixit, MD has no relevant financial relationships with ineligible companies to disclose. Dr. Stephen T. Magill, MD, PhD has no relevant financial relationships with ineligible companies to disclose. Melanie Cole has no relevant financial relationships with ineligible companies to disclose. Dr. Randy Christopher Bowen, MD has no relevant financial relationships with ineligible companies to disclose.Course Director and planning committee:Dr. Babak Jahromi, MD states he is a PI for IRRAS. All the relevant financial relationships for these individuals have been mitigated. FSM’s CME Leadership, Review Committee, and Staff have no relevant financial relationships with ineligible companies to disclose.Claim your credit >
